Dataset from Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center

The purpose of this study is to assess the feasibility of delivering anti-SARS-CoV-2
convalescent plasma to hospitalized patients with severe or life-threatening COVID-19.

Beyond supportive care, there are currently no proven treatment options for coronavirus
disease (COVID-19), the infection caused by Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2). Human convalescent plasma is an option for treatment of COVID-19 and could be
rapidly available when there are sufficient numbers of people who have recovered and can
donate high titer neutralizing immunoglobulin-containing plasma.

Hypothesis: Collecting and administering convalescent plasma requires a level of logistical
coordination that is not available in all centers.

Objective: To establish feasibility for a hospital-based integrated system to collect and
administer convalescent plasma to patients with severe or life-threatening COVID-19.